What's Happening?
Zai Lab Limited has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its drug, zocilurtatug pelitecan (zoci), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs). These are aggressive
malignancies with no approved therapies, affecting approximately 100,000 people worldwide. The Fast Track status is intended to expedite the development and review of drugs that address unmet medical needs or treat serious conditions. Zoci, a Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate, has shown promising preliminary clinical data, including a 38.2% objective response rate in heavily pretreated patients. The drug is currently in a Phase 1b/2 clinical trial, and Zai Lab is actively engaging with health authorities to advance its clinical development.
Why It's Important?
The FDA's Fast Track Designation for zoci underscores the significant potential of this investigational drug to provide a new treatment option for patients with difficult-to-treat cancers. This designation allows for more frequent interactions with the FDA, potentially leading to accelerated approval and priority review. For patients with epNECs, who currently have limited treatment options, zoci could represent a significant advancement in care. The drug's development is part of Zai Lab's broader strategy to address significant unmet medical needs in oncology, which could have substantial implications for the biopharmaceutical industry and patient outcomes.
What's Next?
Zai Lab plans to continue its engagement with health authorities to advance zoci through the necessary clinical trials. The company aims to complete registration-enabling studies for zoci across various cancer types by the end of 2026. If successful, zoci could become a new standard of care for previously treated extensive-stage small cell lung cancer and other neuroendocrine carcinomas. The Fast Track Designation may facilitate a quicker path to market, potentially allowing patients to access this treatment sooner.
